Literature DB >> 22961216

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Tomohiko Kamimura, Toshihiro Miyamoto, Shuichiro Takashima, Noriko Yokota, Yong Chong, Yoshikiyo Ito, Koichi Akashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961216     DOI： 10.1007/s12185-012-1167-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Authors:  Karam M Obeid; Richard Ferrara; Mamta Sharma
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-24

2.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

Authors:  Craig B Reeder; Donna E Reece; Vishal Kukreti; Christine Chen; Suzanne Trudel; Kristina Laumann; Joseph Hentz; Nicholas A Pirooz; Jesus G Piza; Rodger Tiedemann; Joseph R Mikhael; Peter L Bergsagel; Jose F Leis; Rafael Fonseca; Alexander K Stewart
Journal:  Blood       Date:  2010-04-22       Impact factor: 22.113

3.  Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.

Authors:  Toshihiro Fukushima; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomomi Sato; Tomoyuki Sakai; Toshioki Sawaki; Yoshimasa Fujita; Masao Tanaka; Yasufumi Masaki; Hideo Nakajima; Yoshiharu Motoo; Hisanori Umehara
Journal:  Anticancer Res       Date:  2011-06       Impact factor: 2.480

4.  Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Authors:  Bertrand Arnulf; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Helgi van de Velde; Huaibao Feng; Andrew Cakana; William Deraedt; Philippe Moreau
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

5.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

6.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Journal:  Br J Haematol       Date:  2009-01-16       Impact factor: 6.998

7.  Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Authors:  Philippe Moreau; Valerie Coiteux; Cyrille Hulin; Xavier Leleu; Helgi van de Velde; Milin Acharya; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2008-09-02       Impact factor: 9.941

8.  Skin lesions induced by bortezomib.

Authors:  Ludek Pour; Roman Hajek; Adam Zdenek; Marta Krejci; Andrea Krivanova; Jiri Vorlicek
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941
  8 in total
  3 in total

1.  Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.

Authors:  Shuichiro Takashima; Toshihiro Miyamoto; Masanori Kadowaki; Yoshikiyo Ito; Takatoshi Aoki; Ken Takase; Takahiro Shima; Goichi Yoshimoto; Koji Kato; Tsuyoshi Muta; Motoaki Shiratsuchi; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Tomohiko Kamimura; Koichi Akashi
Journal:  Int J Hematol       Date:  2014-06-14       Impact factor: 2.490

2.  High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.

Authors:  Tomohiko Kamimura; Toshihiro Miyamoto; Noriko Yokota; Takatoshi Aoki; Yoshikiyo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-11-19       Impact factor: 2.490

Review 3.  Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Authors:  Maria Teresa Petrucci; Paola Finsinger; Marta Chisini; Fabiana Gentilini
Journal:  Patient Prefer Adherence       Date:  2014-07-04       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.